Aim: Targeting 5-HT 1A receptor (5-HT 1A R) as a strategy for CNS disorders and pain control. Methodology: A series of 1,3-dioxolane-based 2-heteroaryl-phenoxyethylamines was synthesized by a convergent approach and evaluated at α 1 -adrenoceptors and 5-HT 1A R by binding and functional experiments. Absorption, distribution, metabolism, excretion and toxicity prediction studies were performed to explore the drug-likeness of the compounds. Results & conclusion: The most promising compound, the pyridin-4-yl derivative, emerged as a potent and selective 5-HT 1A R agonist (pKi = 9.2; pD2 = 8.83; 5-HT 1A /α1 = 135). In vitro it was able to permeate by passive diffusion MDCKII-MDR1 monolayer mimicking the blood-brain barrier and showed promising neuroprotective activity.

Synthesis and biological evaluation of 1,3-dioxolane-based 5-HT 1A receptor agonists for CNS disorders and neuropathic pain

Ronsisvalle S.;
2018-01-01

Abstract

Aim: Targeting 5-HT 1A receptor (5-HT 1A R) as a strategy for CNS disorders and pain control. Methodology: A series of 1,3-dioxolane-based 2-heteroaryl-phenoxyethylamines was synthesized by a convergent approach and evaluated at α 1 -adrenoceptors and 5-HT 1A R by binding and functional experiments. Absorption, distribution, metabolism, excretion and toxicity prediction studies were performed to explore the drug-likeness of the compounds. Results & conclusion: The most promising compound, the pyridin-4-yl derivative, emerged as a potent and selective 5-HT 1A R agonist (pKi = 9.2; pD2 = 8.83; 5-HT 1A /α1 = 135). In vitro it was able to permeate by passive diffusion MDCKII-MDR1 monolayer mimicking the blood-brain barrier and showed promising neuroprotective activity.
2018
5-HT ; 1A; receptor agonist ; antinociceptive activity; neuroprotection; α ; 1; -adrenoceptors ; Central Nervous System Diseases; Dioxolanes; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuralgia; Neuroprotective Agents; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Structure-Activity Relationship
File in questo prodotto:
File Dimensione Formato  
Silvia Franchini 2018.pdf

solo gestori archivio

Tipologia: Documento in Post-print
Dimensione 718.41 kB
Formato Adobe PDF
718.41 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/402079
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact